The Manufacturers Life Insurance Company Makes New $67,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF)

The Manufacturers Life Insurance Company acquired a new stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 15,487 shares of the company’s stock, valued at approximately $67,000.

Other large investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its holdings in shares of Cardiff Oncology by 68.7% in the fourth quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company’s stock valued at $1,253,000 after purchasing an additional 117,514 shares in the last quarter. HB Wealth Management LLC bought a new position in Cardiff Oncology during the 4th quarter valued at $105,000. American Century Companies Inc. lifted its stake in Cardiff Oncology by 12.8% during the 4th quarter. American Century Companies Inc. now owns 53,955 shares of the company’s stock valued at $234,000 after acquiring an additional 6,140 shares in the last quarter. Rhumbline Advisers boosted its holdings in Cardiff Oncology by 24.0% during the 4th quarter. Rhumbline Advisers now owns 53,172 shares of the company’s stock worth $231,000 after acquiring an additional 10,290 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Cardiff Oncology by 291.9% in the 3rd quarter. Barclays PLC now owns 53,089 shares of the company’s stock worth $141,000 after acquiring an additional 39,542 shares in the last quarter. Institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Price Performance

Shares of Cardiff Oncology stock opened at $2.91 on Tuesday. The firm has a market cap of $193.59 million, a PE ratio of -3.10 and a beta of 1.81. Cardiff Oncology, Inc. has a 1 year low of $2.01 and a 1 year high of $5.64. The stock has a fifty day moving average price of $3.00 and a 200-day moving average price of $3.46.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.09 million. Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. As a group, equities analysts anticipate that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised their price target on shares of Cardiff Oncology from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, May 9th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.